What is the official website of Eye Care ?

The official website of Eye Care is https://www.abbvie.com/science/areas-of-focus/eye-care.html.

What is Eye Care's cybersecurity risk score?

Eye Care has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Eye Care experienced?

According to Rankiteo, Eye Care currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Eye Care been affected by any supply chain cyber incidents ?

According to Rankiteo, Eye Care has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Eye Care have SOC 2 Type 1 certification ?

According to Rankiteo, Eye Care is not certified under SOC 2 Type 1.

Does Eye Care have SOC 2 Type 2 certification ?

According to Rankiteo, Eye Care does not hold a SOC 2 Type 2 certification.

Does Eye Care comply with GDPR ?

According to Rankiteo, Eye Care is not listed as GDPR compliant.

Does Eye Care have PCI DSS certification ?

According to Rankiteo, Eye Care does not currently maintain PCI DSS compliance.

Does Eye Care comply with HIPAA ?

According to Rankiteo, Eye Care is not compliant with HIPAA regulations.

Does Eye Care have ISO 27001 certification ?

According to Rankiteo,Eye Care is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Eye Care operate in ?

Eye Care operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Eye Care have ?

Eye Care employs approximately 0 people worldwide.

Does Eye Care own any subsidiaries ?

Eye Care presently has no subsidiaries across any sectors.

How many LinkedIn followers does Eye Care have ?

Eye Care's official LinkedIn profile has approximately 437 followers.

What is the NAICS classification code for Eye Care ?

Eye Care is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Eye Care have a Crunchbase profile ?

No, Eye Care does not have a profile on Crunchbase.

Does Eye Care have a LinkedIn profile ?

Yes, Eye Care maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie-eye-care.

How many cybersecurity incidents has Eye Care experienced ?

As of June 11, 2026, Rankiteo reports that Eye Care has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Eye Care have ?

Eye Care has an estimated 5,684 peer or competitor companies worldwide.

What types of cybersecurity incidents has Eye Care faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Eye Care

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Eye Care Vendor Cyber Rating & Cyber Score

abbvie.com

Add Your Compliance Badge

Follow AbbVie’s Eye Care page for news and updates about our commitment to help people living with retina-related diseases, glaucoma, dry eye disease and refractive conditions. Our goal is to preserve and protect vision, with patients at the heart of everything we do.

Eye Care A.I CyberSecurity Scoring

Scoring History

Eye Care

Eye Care CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

Eye Care

Breach

100

6/2023

ABB0473723

Loading…

A.I.

Eye Care Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Eye Care

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Eye Care in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Eye Care in 2026.

Incident Types Eye Care vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Eye Care in 2026.

Incident History - Eye Care (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Eye Care Subsidiaries

Eye Care

Pharmaceutical Manufacturing

Website: https://www.abbvie.com/science/areas-of-focus/eye-care.html

Company Size: 0

AbbViePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Allergan AestheticsPharmaceutical Manufacturing

CoolSculptingMedical Equipment Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

JUVÉDERM® Collection of FillersPharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

OncologyPharmaceutical Manufacturing

ImmunologyPharmaceutical Manufacturing

Loading…

Eye Care Similar Companies

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Eye Care CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 29, 2025 07:06 PM

Stakeholders discuss initiatives to achieve USD 1 trillion vision

Lucknow: To fast-track infrastructure and industrial growth in the state, Invest UP, in collaboration with NITI Aayog and key state...

Read Article

October 28, 2025 04:07 PM

Google probes exploitation of critical Windows service CVE

Researchers have traced the threat activity to a newly identified hacker, while separate evidence points to more than one variant.

Read Article

October 26, 2025 07:00 AM

Healthcare Data Breach Statistics

The HIPAA Journal has compiled healthcare data breach statistics from October 2009, when the Department of Health and Human Services (HHS)...

Read Article

October 22, 2025 01:13 PM

Oregon Eye Care Provider and New York Children’s Center Announce Hacking Incidents

Cyberattacks have recently been announced by River City Eye in Oregon and Elmcrest Children's Center in New York. River City Eye Care River...

Read Article

October 21, 2025 12:26 AM

River City Eye Care Data Breach Lawsuit Investigation

If you were affected by the River City Eye Care data breach, you may be entitled to compensation.

Read Article

September 30, 2025 06:12 PM

What You’ve Always Wanted to Know About Data Security but Were Afraid to Ask

As an IT professional, you're likely concerned about cybersecurity and the implications of a ransomware attack…and for good reason.

Read Article

September 20, 2025 07:00 AM

Zenni Optical Hosts Expert Panel Following the Launch of EyeQLenz With Zenni ID Guard

NOVATO, Calif.—Zenni Optical announced it convened a panel this week called “Protect Your Eyes, Your Choice, Your Way,” bringing together...

Read Article

September 18, 2025 01:55 AM

Florida patients at risk after major data breach at eye care provider

A significant data breach at Retina Group of Florida has compromised the personal and medical information of nearly 153000 patients.

Read Article

September 17, 2025 07:00 AM

The VA eyes ‘aggressive deployment’ of AI; More than 100 cybersecurity experts urge senators to confirm Pentagon CIO

Lawmakers pressed Charles Worthington on data privacy and workforce readiness as the VA pushes ahead with AI.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-53465

SUMMARY

ImageMagick is free and open-source software used for editing and manipulating digital images. Prior to version 7.1.2-25, a crafted multi-frame can result in a heap buffer over-write when encoding it with the SF3 encoder. This issue has been patched in version 7.1.2-25.

Published

Date2026-06-10

Updated

Date2026-06-10

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.5

REFERENCES

https://github.com/ImageMagick/ImageMagick/security/advisories/GHSA-44cp-c3ww-9rv5

CVE-2026-53464

SUMMARY

ImageMagick is free and open-source software used for editing and manipulating digital images. Prior to version 7.1.2-25, when providing invalid options to the wand option parser a small memory leak will occur. This issue has been patched in version 7.1.2-25.

Published

Date2026-06-10

Updated

Date2026-06-10

RISK INFORMATION (Score: 4)

cvss3

Base Score: 4.0

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

2.5

REFERENCES

https://github.com/ImageMagick/ImageMagick/security/advisories/GHSA-j989-f892-2335

CVE-2026-53463

SUMMARY

ImageMagick is free and open-source software used for editing and manipulating digital images. Prior to versions 6.9.13-50 and 7.1.2-25, when passing incorrect arguments in the distort operation a null pointer deference will occur. This issue has been patched in versions 6.9.13-50 and 7.1.2-25.

Published

Date2026-06-10

Updated

Date2026-06-10

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://github.com/ImageMagick/ImageMagick/security/advisories/GHSA-p9rq-q46c-g4x6

CVE-2026-53462

SUMMARY

ImageMagick is free and open-source software used for editing and manipulating digital images. Prior to versions 6.9.13-50 and 7.1.2-25, when an allocation fails in CheckPrimitiveExtent this can result in a heap-use-after-free and result in a crash. This issue has been patched in versions 6.9.13-50 and 7.1.2-25.

Published

Date2026-06-10

Updated

Date2026-06-10

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

https://github.com/ImageMagick/ImageMagick/security/advisories/GHSA-px7q-ggqj-hcf2

CVE-2026-53461

SUMMARY

ImageMagick is free and open-source software used for editing and manipulating digital images. Prior to versions 6.9.13-50 and 7.1.2-25, an incorrect loop in the ICON decoder can result in an out of bounds heap write resulting in a crash. This issue has been patched in versions 6.9.13-50 and 7.1.2-25.

Published

Date2026-06-10

Updated

Date2026-06-10

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

https://github.com/ImageMagick/ImageMagick/security/advisories/GHSA-g22q-f7gc-5jhr

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…